Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009
Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Effect of codeine (30mg) with paracetamol (650mg) on post bronchoscopy coughing –an open labeled placebo control trial Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
LATE-BREAKING ABSTRACT: Umeclidinium (GSK573719) dose response and dosing interval in COPD Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012
Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone (S/F) Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomized clinical trial Source: Eur Respir J 2001; 18: Suppl. 33, 12s Year: 2001
Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Treatment of patients with uncontrolled asthma using high dose inhaled corticosteroids administered by controlled inhalation – a retrospective analysis Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Exploration of sedative dose and patient acceptability scores after flexible bronchoscopy – An observational study Source: Annual Congress 2010 - New toys, old problems: extrapleural lung volume reduction, sedation and comfort in bronchoscopy Year: 2010
Low dose inhaled LPS challenge – Reproducibility of the inflammatory response Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012